First Online: 28 July 2016
Change Date: 29 October 2018
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/S41572-018-0043-2
: C.M.G. has received research grants from the Alpha-1 Foundation and received an honorarium for educational materials from Vertex Pharmaceuticals. J.T. has served as a consultant for Alnylam Pharmaceuticals, Arrowhead Research, Proteostasis Therapeutics, Isis Pharmaceuticals (now Ionis Pharmaceuticals), Editas Medicine, Genkyotex, GLG Pharma, INSERM, Intellia Therapeutics, Retrophin, RxCelerate and Velgene. He also received honoraria for speaking from the Alpha-1 Foundation and the Cystic Fibrosis Foundation and research grants or support from the Alpha-1 Foundation, US NIH, Alnylam Pharmaceuticals, Arrowhead Research and the Cardinal Glennon Children's Foundation. M.L.B. has received research support for clinical trials from Baxalta, Kamada and Grifols, is an owner of GeneAidyx, a genetic diagnostic company, and holds patents for α1-antitrypsin gene therapy and compounds to modify α1-antitrypsin secretion. D.A.L. has received research funding from GlaxoSmithKline to develop small-molecule therapies for α1-antitrypsin deficiency. He was also chair of the GlaxoSmithKline Respiratory Therapy Area Board between 2012 and 2015. J.K.S. has served as a consultant for Kamada, Grifols, Arrowhead Research, CSL Behring, Baxalta, Pfizer and Boehringer-Ingelheim. He is a member of the board of directors of the Alpha-1 Foundation, and the Medical and Scientific Advisory Council for both the COPD Foundation and the Alpha-1 Foundation. N.G.M. has served as a consultant for Chiesi and Bayer and received honoraria for speaking from Chiesi, Grifols and CSL Behring. He also received grants or research support from Chiesi, Grifols, Vertex and the Alpha-1 Foundation. S.J.M. and I.F. declare no competing interests.